PEAK6 Investments’s Heron Therapeutics HRTX Stock Holding History

PEAK6 Investments’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-20,000	Closed	-$235K	–	4560
2020 Q1	$235K	Buy	+20,000	New	+$376K	﹤0.01%	2707

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PEAK6 Investments's HRTX Position: Q2 2020 in Review

PEAK6 Investments sold out of Heron Therapeutics (HRTX) in Q2 2020, closing a stake of 20,000 shares — an estimated $235K sold.

PEAK6 Investments first reported a position in HRTX in Q1 2020 and held it in 1 quarter. The position peaked at $235K in Q1 2020. 190 funds tracked by Wall St. Rank hold HRTX as of Q2 2020.

PEAK6 Investments reported no remaining Heron Therapeutics position as of Q2 2020 after selling out during the quarter.
PEAK6 Investments sold 20,000 Heron Therapeutics shares in Q2 2020, an estimated $235K.
PEAK6 Investments first reported a position in Heron Therapeutics in Q1 2020 and held it in 1 quarter.
PEAK6 Investments's Heron Therapeutics position peaked at $235K in Q1 2020.
190 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2020.

Based on PEAK6 Investments's 13F filing for Q2 2020, filed 14 Aug 2020.